Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset.
J Infect Dis
; 215(12): 1807-1815, 2017 06 15.
Article
en En
| MEDLINE
| ID: mdl-28472421
ABSTRACT
Middle East respiratory syndrome coronavirus (MERS-CoV) infection in humans is highly lethal, with a fatality rate of 35%. New prophylactic and therapeutic strategies to combat human infections are urgently needed. We isolated a fully human neutralizing antibody, MCA1, from a human survivor. The antibody recognizes the receptor-binding domain of MERS-CoV S glycoprotein and interferes with the interaction between viral S and the human cellular receptor human dipeptidyl peptidase 4 (DPP4). To our knowledge, this study is the first to report a human neutralizing monoclonal antibody that completely inhibits MERS-CoV replication in common marmosets. Monotherapy with MCA1 represents a potential alternative treatment for human infections with MERS-CoV worthy of evaluation in clinical settings.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Replicación Viral
/
Infecciones por Coronavirus
/
Dipeptidil Peptidasa 4
/
Anticuerpos Neutralizantes
/
Coronavirus del Síndrome Respiratorio de Oriente Medio
/
Anticuerpos Monoclonales
Tipo de estudio:
Clinical_trials
Límite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
J Infect Dis
Año:
2017
Tipo del documento:
Article
Pais de publicación:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA